CoLucid Pharmaceuticals Inc (CLCD)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:CoLucid Pharmaceuticals Inc (CLCD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013094
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月27日
◆ページ数:28
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
CoLucid Pharmaceuticals Inc (CoLucid) is a pharmaceutical company that conducts research and develops new therapies. CoLucid’s lead product candidate Lasmiditan (COL-144), is an oral tablet that penetrates the central nervous system and selectively targets 5-HT1F receptors expressed in the trigeminal nerve pathway. It’s been designed to deliver efficacy for the acute treatment of migraine in adults without the vasoconstrictor activity and clinical limitations associated with previous generations of migraine therapies. The company offers oral lasmiditan for the treatment of migraine headaches; and intravenous lasmiditan to treat unspecified headache pain in adults. CoLucid is headquartered in Cambridge, Massachusetts, the US.

CoLucid Pharmaceuticals Inc (CLCD) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
CoLucid Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
CoLucid Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
CoLucid Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
CoLucid Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
CoLucid Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
CoLucid Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
CoLucid Pharma Raises USD37 Million in Series C Financing Round 10
CoLucid Pharma Secures An Additional US$4 Million In Venture Financing 12
Partnerships 13
CoLucid Pharma And Ildong Pharma Enter Into Distribution Agreement For Lasmiditan 13
Equity Offering 14
CoLucid Pharma Prices Public Offering of Shares for USD65 Million 14
CoLucid Pharma Raises USD55 Million in IPO 16
Acquisition 17
Eli Lilly Acquires CoLucid Pharma for USD960 Million in Tender Offer 17
CoLucid Pharmaceuticals Inc – Key Competitors 19
CoLucid Pharmaceuticals Inc – Key Employees 20
CoLucid Pharmaceuticals Inc – Locations And Subsidiaries 21
Head Office 21
Recent Developments 22
Financial Announcements 22
Nov 09, 2016: CoLucid Pharmaceuticals Announces 2016 Third Quarter Results and Corporate Highlights 22
Aug 10, 2016: CoLucid Pharmaceuticals Announces 2016 Second Quarter Results and Corporate Highlights 24
May 11, 2016: CoLucid Pharmaceuticals Announces 2016 First Quarter Results and Corporate Highlights 25
Mar 02, 2016: CoLucid Pharmaceuticals Announces 2015 Fourth Quarter and Year-End Results and Corporate Highlights 26
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
CoLucid Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 2
CoLucid Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
CoLucid Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
CoLucid Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
CoLucid Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
CoLucid Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
CoLucid Pharma Raises USD37 Million in Series C Financing Round 10
CoLucid Pharma Secures An Additional US$4 Million In Venture Financing 12
CoLucid Pharma And Ildong Pharma Enter Into Distribution Agreement For Lasmiditan 13
CoLucid Pharma Prices Public Offering of Shares for USD65 Million 14
CoLucid Pharma Raises USD55 Million in IPO 16
Eli Lilly Acquires CoLucid Pharma for USD960 Million in Tender Offer 17
CoLucid Pharmaceuticals Inc, Key Competitors 19
CoLucid Pharmaceuticals Inc, Key Employees 20

★海外企業調査レポート[CoLucid Pharmaceuticals Inc (CLCD)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Biolase, Inc. (BIOL)-医療機器分野:企業M&A・提携分析
    Summary Biolase, Inc. (Biolase) is medical device company which develops, manufactures, markets and sells dental lasers and related products. It also distributes dental imaging equipment, including cone beam digital x-rays and CAD/CAM intra-oral scanners. The company offers two categories of laser s …
  • 10X Genomics, Inc.:製薬・医療:M&Aディール及び事業提携情報
    Summary 10X Genomics, Inc. (10X Genomics) is engaged in developing an innovative genomics platform. The company’s product pipeline comprises of chromium controller, single cell ATAC sequencer and single cell with barcode technology. It offers single cell gene expression, single cell immune profiling …
  • Evox Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Evox Therapeutics Ltd (Evox Therapeutics) is a biotechnology company focused on harnessing and engineering the natural delivery capabilities of exosomes, to develop novel medicines for various diseases. Its development pipeline is focused in the therapeutic areas of inflammatory, immune dise …
  • Haemonetics Corp (HAE):企業の製品パイプライン分析2018
    Summary Haemonetics Corp (Haemonetics) is a healthcare company that offers blood management technologies and software solutions. Its portfolio includes integrated devices, information management software, and consulting services for improving clinical outcomes. It also offers a comprehensive suite o …
  • Mediobanca Banca di Credito Finanziario S.p.A.:企業の戦略・SWOT・財務分析
    Mediobanca Banca di Credito Finanziario S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Mediobanca Banca di Credito Finanziario S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, ope …
  • Showa Denko K.K.:企業の戦略・SWOT・財務分析
    Showa Denko K.K. - Strategy, SWOT and Corporate Finance Report Summary Showa Denko K.K. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Cesca Therapeutics Inc (KOOL):製品パイプライン分析
    Summary Cesca Therapeutics Inc (Cesca) researches, develops, and commercializes cell based therapeutics for applications in regenerative medicine. Its proprietary technology platform, PXP is used to develop autologous cell-based therapies for the in the vascular and orthopedic markets. Its device di …
  • Axxam SpA-製薬・医療分野:企業M&A・提携分析
    Summary Axxam SpA (Axxam) is a partner research organization that provides drug discovery services. The organization offers drug discovery services such as molecular biology, assay development and reagent provision, compound management, hit characterization and profiling and electrophysiology, among …
  • SurModics Inc (SRDX):企業の財務・戦略的SWOT分析
    SurModics Inc (SRDX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Anheuser-Busch InBev SA/NV:企業の戦略・SWOT・財務分析
    Anheuser-Busch InBev SA/NV - Strategy, SWOT and Corporate Finance Report Summary Anheuser-Busch InBev SA/NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Ossur hf (OSSR)-医療機器分野:企業M&A・提携分析
    Summary Ossur hf. (Ossur) is an orthopedic devices company. It develops, manufactures and sells prosthetics, and bracing and support products. The company’s key areas of expertise include silicone, carbon composites, mechatronics and textiles. Ossur offers ankle and foot supports, knee braces, neck …
  • AptarGroup Inc:企業の戦略・SWOT・財務分析
    AptarGroup Inc - Strategy, SWOT and Corporate Finance Report Summary AptarGroup Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • SAS Institute Inc.:企業の戦略・SWOT・財務分析
    SAS Institute Inc. - Strategy, SWOT and Corporate Finance Report Summary SAS Institute Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Merck & Co., Inc.:企業のM&A・事業提携・投資動向
    Merck & Co., Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Merck & Co., Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Aramark Services Inc (ARMK):企業の財務・戦略的SWOT分析
    Aramark Services Inc (ARMK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Consolidated Edison Company of New York, Inc.:発電所・企業SWOT分析
    Consolidated Edison Company of New York, Inc. - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, in …
  • Adani Enterprises Ltd (ADANIENT):石油・ガス:M&Aディール及び事業提携情報
    Summary Adani Enterprises Ltd (Adani) is a diversified company with operations in resources, logistics and energy. It has interests in various businesses such as coal trading and mining, bunkering, renewable power generation, defense and aerospace, ports and special economic zones (SEZ), logistics, …
  • Vect-Horus SAS:製薬・医療:M&Aディール及び事業提携情報
    Summary Vect-Horus SAS (Vect-Horus) is a biotechnology company that designs and develops peptide-based vectors to facilitate the delivery of drugs or imaging agents into organs including the brain and tumors. The company combines molecules of interest to peptide-vectors that targets receptor mediate …
  • Rashtriya Chemicals and Fertilizers Ltd (RCF):企業の財務・戦略的SWOT分析
    Summary Rashtriya Chemicals and Fertilizers Ltd (RCFL) is a chemical company that manufactures and markets fertilizers and industrial chemicals. The company offers industrial chemicals include methanol, mono methylamine, strong nitric acid, dilute nitric acid, sulphuric acid, sodium nitrite, anhydro …
  • ConocoPhillips:企業の戦略・SWOT・財務情報
    ConocoPhillips - Strategy, SWOT and Corporate Finance Report Summary ConocoPhillips - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆